Weekly Digest - Mar 2024

Weekly Digest - Mar 2024

27 Mar 2024: AstraZeneca India gets dual CDSCO approval for Trastuzumab deruxtecan

  • AstraZeneca Pharma India gains CDSCO approval for Trastuzumab deruxtecan lyophilised powder for solution for infusion 100mg, expanding treatment options in India’s healthcare landscape
  • Expanded indications now cover previously treated HER2-low metastatic breast cancer and locally advanced or metastatic gastric cancer
  • Trastuzumab deruxtecan, earlier DCGI-approved for unresectable or metastatic HER2-positive breast cancer after prior anti-HER2 treatment

For full story click here

Share this

Facebook
fb-share-icon
Twitter
Tweet
LinkedIn
Share
Home